Product Description: Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331./[2]Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.